Jump to:
Ryan Kramer joined Ropes & Gray’s corporate department in 2022. Ryan primarily practices in the intellectual property transactions group, advising life sciences clients on a broad range of strategic transactions, including complex licensing arrangements, collaborations, mergers & acquisitions, and royalty monetization transactions.
During law school, Ryan served as a notes editor for the Boston University Law Review and as a lawyering fellow in the school’s first-year legal writing program. He also served as the networking director for the Health Law Association and worked as a research assistant focusing on consumer protection and privacy law.
Experience
- Advised Viridian Therapeutics in securing up to $300 million in funding from DRI Healthcare Acquisitions in exchange for a royalty on U.S. net sales of Viridian’s thyroid eye disease therapies veligrotug and VRDN-003.
- Advised Viridian Therapeutics in an exclusive license and collaboration agreement with Kissei Pharmaceutical to develop and market thyroid eye disease therapies veligrotug and VRDN-003 in Japan.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist, in a transaction worth up to $2 billion.
- Advised Novo Nordisk in an exclusive license agreement with The United Laboratories to develop, manufacture, and commercialize United’s UBT-251, a triple agonist of the receptors for GLP-1, GIP, and glucagon, for the treatment of diabetes, obesity, and other diseases globally, excluding Greater China, in a transaction worth up to $2 billion.
- Represented Sarepta Therapeutics in a transformational global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple siRNA programs worth up to $11.35 billion.
- Represented Novo Nordisk in a worldwide collaboration with Neomorph Inc. worth up to $1.46 billion to discover, develop and commercialize molecular glue degraders for multiple targets.
- Advised ImmunoGen, Inc. on intellectual property matters related to its $10.1 billion sale to AbbVie Inc.
- Represented Regeneron Pharmaceuticals in its acquisition of 2seventy Bio Inc.’s oncology and autoimmune programs as part of its newly launched R&D unit Regeneron Cell Medicines.
- Represented a multinational pharmaceutical company in a strategic transaction with a Chinese biotechnology company to develop potential first-in-class peptide therapeutics worth up to $3.5 billion.
- Represented a leading investment management firm in the sale of its royalty interest in a therapy for the treatment of cardiovascular disease.
- Represented the lead underwriters in the initial public offering of Loar Holdings Inc.